 Shahram Oveisgharan
Concepts (237)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinsonian Disorders | 6 | 2022 | 210 | 3.540 |
Why?
| | Brain | 10 | 2022 | 1655 | 3.280 |
Why?
| | Stroke | 13 | 2021 | 367 | 3.150 |
Why?
| | Brain Ischemia | 6 | 2020 | 122 | 1.770 |
Why?
| | Alzheimer Disease | 6 | 2020 | 1829 | 1.740 |
Why?
| | Intracranial Arteriosclerosis | 2 | 2022 | 60 | 1.690 |
Why?
| | Apolipoprotein E4 | 3 | 2020 | 218 | 1.500 |
Why?
| | Aged, 80 and over | 20 | 2021 | 5234 | 1.380 |
Why?
| | Aged | 31 | 2022 | 10295 | 1.260 |
Why?
| | Dementia, Vascular | 2 | 2016 | 42 | 1.220 |
Why?
| | Male | 42 | 2022 | 17583 | 1.150 |
Why?
| | Female | 43 | 2022 | 18253 | 1.140 |
Why?
| | Disease Progression | 5 | 2021 | 861 | 1.100 |
Why?
| | Incidence | 14 | 2021 | 829 | 1.060 |
Why?
| | Atherosclerosis | 2 | 2022 | 57 | 1.030 |
Why?
| | Hypertension | 7 | 2020 | 283 | 1.020 |
Why?
| | Cardiovascular Diseases | 10 | 2018 | 410 | 0.990 |
Why?
| | Humans | 48 | 2022 | 31481 | 0.960 |
Why?
| | Neuropsychological Tests | 4 | 2015 | 1300 | 0.960 |
Why?
| | Iran | 18 | 2021 | 36 | 0.920 |
Why?
| | Dementia | 3 | 2020 | 545 | 0.900 |
Why?
| | tau Proteins | 2 | 2020 | 174 | 0.900 |
Why?
| | Executive Function | 2 | 2015 | 109 | 0.890 |
Why?
| | Aging | 8 | 2021 | 1614 | 0.890 |
Why?
| | Independent Living | 2 | 2021 | 257 | 0.850 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2022 | 81 | 0.850 |
Why?
| | Risk Factors | 17 | 2021 | 2664 | 0.810 |
Why?
| | Longitudinal Studies | 11 | 2021 | 1452 | 0.810 |
Why?
| | Health Status | 2 | 2021 | 249 | 0.790 |
Why?
| | Mobility Limitation | 1 | 2021 | 100 | 0.790 |
Why?
| | Cerebral Amyloid Angiopathy | 1 | 2021 | 101 | 0.790 |
Why?
| | Prefrontal Cortex | 2 | 2021 | 152 | 0.780 |
Why?
| | White Matter | 1 | 2021 | 145 | 0.770 |
Why?
| | Eyeglasses | 1 | 2019 | 3 | 0.770 |
Why?
| | Beta Rhythm | 1 | 2019 | 4 | 0.770 |
Why?
| | Transcranial Magnetic Stimulation | 1 | 2019 | 18 | 0.770 |
Why?
| | Child Development | 1 | 2020 | 78 | 0.770 |
Why?
| | Vision, Ocular | 1 | 2019 | 13 | 0.770 |
Why?
| | Agnosia | 1 | 2019 | 10 | 0.760 |
Why?
| | Mental Health | 1 | 2021 | 119 | 0.760 |
Why?
| | Disabled Persons | 1 | 2021 | 119 | 0.750 |
Why?
| | Brain Infarction | 1 | 2020 | 78 | 0.740 |
Why?
| | Blood Pressure | 2 | 2020 | 260 | 0.740 |
Why?
| | Visual Perception | 1 | 2019 | 69 | 0.730 |
Why?
| | Exercise | 2 | 2020 | 454 | 0.710 |
Why?
| | Motor Activity | 3 | 2019 | 397 | 0.700 |
Why?
| | Cohort Studies | 13 | 2021 | 2014 | 0.690 |
Why?
| | Amyloid beta-Peptides | 1 | 2020 | 248 | 0.690 |
Why?
| | Cerebral Hemorrhage | 5 | 2021 | 141 | 0.670 |
Why?
| | Transcranial Direct Current Stimulation | 1 | 2017 | 8 | 0.670 |
Why?
| | Sex Characteristics | 1 | 2018 | 128 | 0.660 |
Why?
| | Upper Extremity | 1 | 2017 | 46 | 0.650 |
Why?
| | Age Factors | 7 | 2021 | 943 | 0.600 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 2015 | 41 | 0.590 |
Why?
| | Autopsy | 4 | 2021 | 340 | 0.590 |
Why?
| | Aspirin | 1 | 2015 | 90 | 0.550 |
Why?
| | Cognition | 2 | 2020 | 1206 | 0.530 |
Why?
| | Middle Aged | 26 | 2021 | 11209 | 0.480 |
Why?
| | Canada | 4 | 2015 | 57 | 0.420 |
Why?
| | Obesity | 4 | 2019 | 338 | 0.370 |
Why?
| | Waist Circumference | 4 | 2019 | 34 | 0.360 |
Why?
| | Follow-Up Studies | 8 | 2020 | 2028 | 0.350 |
Why?
| | Time Factors | 4 | 2019 | 1902 | 0.330 |
Why?
| | Cognition Disorders | 3 | 2016 | 1075 | 0.330 |
Why?
| | Genetic Predisposition to Disease | 3 | 2018 | 462 | 0.320 |
Why?
| | Recovery of Function | 2 | 2019 | 309 | 0.310 |
Why?
| | Triglycerides | 2 | 2017 | 50 | 0.310 |
Why?
| | Adult | 16 | 2021 | 9779 | 0.300 |
Why?
| | Disability Evaluation | 2 | 2019 | 332 | 0.300 |
Why?
| | Language | 1 | 2006 | 79 | 0.290 |
Why?
| | Prospective Studies | 7 | 2021 | 1934 | 0.280 |
Why?
| | Proportional Hazards Models | 4 | 2020 | 390 | 0.280 |
Why?
| | Waist-Hip Ratio | 5 | 2019 | 17 | 0.280 |
Why?
| | Cross-Sectional Studies | 3 | 2018 | 986 | 0.280 |
Why?
| | Hospitalization | 1 | 2007 | 359 | 0.270 |
Why?
| | Treatment Outcome | 5 | 2019 | 3910 | 0.260 |
Why?
| | Activities of Daily Living | 1 | 2006 | 495 | 0.240 |
Why?
| | Risk Assessment | 4 | 2021 | 806 | 0.240 |
Why?
| | Smoking | 3 | 2020 | 202 | 0.240 |
Why?
| | Case-Control Studies | 6 | 2021 | 687 | 0.230 |
Why?
| | Migraine Disorders | 1 | 2021 | 22 | 0.220 |
Why?
| | Ontario | 1 | 2021 | 18 | 0.220 |
Why?
| | Diabetes Mellitus | 2 | 2020 | 150 | 0.210 |
Why?
| | Life Style | 2 | 2020 | 219 | 0.210 |
Why?
| | Potassium | 1 | 2021 | 71 | 0.210 |
Why?
| | Nerve Block | 1 | 2021 | 58 | 0.210 |
Why?
| | Sodium | 1 | 2021 | 81 | 0.210 |
Why?
| | Peptides | 1 | 2021 | 116 | 0.200 |
Why?
| | Sex Factors | 2 | 2020 | 542 | 0.200 |
Why?
| | Cerebrovascular Disorders | 1 | 2021 | 123 | 0.190 |
Why?
| | Movement Disorders | 1 | 2021 | 150 | 0.190 |
Why?
| | TDP-43 Proteinopathies | 1 | 2021 | 102 | 0.190 |
Why?
| | Psychomotor Performance | 1 | 2021 | 258 | 0.190 |
Why?
| | Residence Characteristics | 2 | 2012 | 226 | 0.190 |
Why?
| | Parkinson Disease | 2 | 2021 | 1180 | 0.190 |
Why?
| | Apolipoproteins E | 1 | 2020 | 205 | 0.180 |
Why?
| | Heredity | 1 | 2018 | 8 | 0.180 |
Why?
| | Linear Models | 1 | 2020 | 276 | 0.180 |
Why?
| | Functional Laterality | 1 | 2019 | 96 | 0.180 |
Why?
| | Pedigree | 1 | 2018 | 72 | 0.180 |
Why?
| | Glycogen Storage Disease Type III | 1 | 2018 | 1 | 0.180 |
Why?
| | Glycogen | 1 | 2018 | 11 | 0.180 |
Why?
| | Arteriolosclerosis | 1 | 2018 | 48 | 0.180 |
Why?
| | Chi-Square Distribution | 1 | 2018 | 178 | 0.170 |
Why?
| | Combined Modality Therapy | 1 | 2019 | 456 | 0.170 |
Why?
| | Milk | 1 | 2017 | 10 | 0.170 |
Why?
| | Nonlinear Dynamics | 1 | 2017 | 19 | 0.170 |
Why?
| | Pilot Projects | 1 | 2019 | 455 | 0.170 |
Why?
| | CADASIL | 1 | 2017 | 1 | 0.170 |
Why?
| | Amphetamine-Related Disorders | 1 | 2016 | 10 | 0.160 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2016 | 8 | 0.160 |
Why?
| | Menopause | 1 | 2018 | 121 | 0.160 |
Why?
| | alpha-Synuclein | 1 | 2018 | 147 | 0.160 |
Why?
| | Vasodilation | 1 | 2016 | 20 | 0.160 |
Why?
| | Genotype | 1 | 2018 | 423 | 0.160 |
Why?
| | Research Design | 1 | 2018 | 238 | 0.160 |
Why?
| | DNA-Binding Proteins | 1 | 2018 | 264 | 0.160 |
Why?
| | Feasibility Studies | 1 | 2017 | 281 | 0.150 |
Why?
| | Chicago | 1 | 2020 | 955 | 0.150 |
Why?
| | Tropanes | 1 | 2015 | 4 | 0.150 |
Why?
| | Central Nervous System Stimulants | 1 | 2016 | 57 | 0.150 |
Why?
| | Organotechnetium Compounds | 1 | 2015 | 9 | 0.150 |
Why?
| | Risk Reduction Behavior | 1 | 2016 | 59 | 0.150 |
Why?
| | Methamphetamine | 1 | 2016 | 47 | 0.150 |
Why?
| | Blood Chemical Analysis | 1 | 2015 | 17 | 0.150 |
Why?
| | Cholesterol, HDL | 1 | 2015 | 34 | 0.150 |
Why?
| | Mutation | 1 | 2018 | 464 | 0.150 |
Why?
| | Child | 1 | 2020 | 1572 | 0.140 |
Why?
| | Predictive Value of Tests | 2 | 2015 | 637 | 0.140 |
Why?
| | Myocardial Ischemia | 1 | 2016 | 63 | 0.140 |
Why?
| | Prediabetic State | 1 | 2014 | 4 | 0.140 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2015 | 84 | 0.140 |
Why?
| | Incidental Findings | 1 | 2014 | 20 | 0.130 |
Why?
| | Heart Rate | 1 | 2014 | 161 | 0.130 |
Why?
| | Interviews as Topic | 2 | 2019 | 152 | 0.120 |
Why?
| | Memory | 1 | 2015 | 343 | 0.120 |
Why?
| | ROC Curve | 3 | 2019 | 153 | 0.120 |
Why?
| | Rural Population | 1 | 2012 | 26 | 0.110 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2014 | 224 | 0.110 |
Why?
| | Urban Population | 1 | 2012 | 161 | 0.110 |
Why?
| | Quality of Life | 1 | 2016 | 663 | 0.100 |
Why?
| | Efferent Pathways | 1 | 2008 | 1 | 0.090 |
Why?
| | Neural Conduction | 1 | 2008 | 12 | 0.090 |
Why?
| | Logistic Models | 1 | 2010 | 479 | 0.090 |
Why?
| | Reproducibility of Results | 2 | 2011 | 886 | 0.080 |
Why?
| | Age Distribution | 1 | 2007 | 110 | 0.080 |
Why?
| | Skin | 1 | 2008 | 136 | 0.080 |
Why?
| | Middle East | 2 | 2017 | 5 | 0.080 |
Why?
| | Action Potentials | 1 | 2008 | 143 | 0.080 |
Why?
| | Developing Countries | 2 | 2018 | 22 | 0.080 |
Why?
| | Comorbidity | 2 | 2021 | 562 | 0.080 |
Why?
| | Diabetes Complications | 2 | 2017 | 74 | 0.080 |
Why?
| | Europe | 2 | 2016 | 88 | 0.070 |
Why?
| | Evidence-Based Medicine | 2 | 2018 | 239 | 0.070 |
Why?
| | Odds Ratio | 2 | 2017 | 327 | 0.070 |
Why?
| | Severity of Illness Index | 2 | 2012 | 1240 | 0.070 |
Why?
| | Body Mass Index | 2 | 2019 | 458 | 0.070 |
Why?
| | Clinical Trials as Topic | 1 | 2006 | 378 | 0.070 |
Why?
| | Angina, Unstable | 2 | 2014 | 13 | 0.070 |
Why?
| | Death, Sudden, Cardiac | 2 | 2014 | 30 | 0.060 |
Why?
| | Prognosis | 2 | 2018 | 1028 | 0.060 |
Why?
| | Prevalence | 2 | 2016 | 544 | 0.060 |
Why?
| | Myocardial Infarction | 2 | 2014 | 187 | 0.060 |
Why?
| | Health Surveys | 2 | 2013 | 102 | 0.060 |
Why?
| | Triamcinolone | 1 | 2021 | 7 | 0.060 |
Why?
| | Lidocaine | 1 | 2021 | 44 | 0.060 |
Why?
| | Potassium, Dietary | 1 | 2021 | 1 | 0.050 |
Why?
| | Headache | 1 | 2021 | 52 | 0.050 |
Why?
| | Sodium, Dietary | 1 | 2021 | 8 | 0.050 |
Why?
| | Causality | 1 | 2021 | 58 | 0.050 |
Why?
| | Glomerular Filtration Rate | 1 | 2021 | 77 | 0.050 |
Why?
| | Retrospective Studies | 1 | 2010 | 3591 | 0.050 |
Why?
| | Analysis of Variance | 1 | 2021 | 364 | 0.050 |
Why?
| | Young Adult | 2 | 2018 | 2277 | 0.050 |
Why?
| | Likelihood Functions | 1 | 2019 | 31 | 0.050 |
Why?
| | Waist-Height Ratio | 1 | 2019 | 6 | 0.050 |
Why?
| | Blood Pressure Determination | 1 | 2019 | 22 | 0.050 |
Why?
| | Anthropometry | 1 | 2019 | 56 | 0.050 |
Why?
| | Adiposity | 1 | 2019 | 51 | 0.050 |
Why?
| | Gene-Environment Interaction | 1 | 2018 | 19 | 0.050 |
Why?
| | Glycogen Debranching Enzyme System | 1 | 2018 | 1 | 0.040 |
Why?
| | Physical Examination | 1 | 2019 | 116 | 0.040 |
Why?
| | Developed Countries | 1 | 2018 | 3 | 0.040 |
Why?
| | Mediterranean Region | 1 | 2017 | 3 | 0.040 |
Why?
| | Epigenesis, Genetic | 1 | 2018 | 95 | 0.040 |
Why?
| | Age of Onset | 1 | 2018 | 113 | 0.040 |
Why?
| | Patient Outcome Assessment | 1 | 2018 | 50 | 0.040 |
Why?
| | Microvessels | 1 | 2017 | 17 | 0.040 |
Why?
| | Phenotype | 1 | 2018 | 379 | 0.040 |
Why?
| | Survival Analysis | 1 | 2018 | 379 | 0.040 |
Why?
| | Poverty | 1 | 2018 | 104 | 0.040 |
Why?
| | Health Services Accessibility | 1 | 2018 | 113 | 0.040 |
Why?
| | Nitroglycerin | 1 | 2016 | 4 | 0.040 |
Why?
| | Carotid Artery, Common | 1 | 2016 | 9 | 0.040 |
Why?
| | Apolipoproteins B | 1 | 2016 | 2 | 0.040 |
Why?
| | Carotid Intima-Media Thickness | 1 | 2016 | 22 | 0.040 |
Why?
| | Liver Transplantation | 1 | 2018 | 114 | 0.040 |
Why?
| | Asia | 1 | 2016 | 11 | 0.040 |
Why?
| | Overweight | 1 | 2017 | 67 | 0.040 |
Why?
| | Africa | 1 | 2016 | 12 | 0.040 |
Why?
| | Apolipoprotein A-I | 1 | 2016 | 6 | 0.040 |
Why?
| | Australia | 1 | 2016 | 50 | 0.040 |
Why?
| | International Cooperation | 1 | 2016 | 38 | 0.040 |
Why?
| | Vasodilator Agents | 1 | 2016 | 34 | 0.040 |
Why?
| | Regression Analysis | 1 | 2017 | 319 | 0.040 |
Why?
| | Obesity, Abdominal | 1 | 2016 | 22 | 0.040 |
Why?
| | China | 1 | 2016 | 66 | 0.040 |
Why?
| | Risk | 1 | 2016 | 228 | 0.040 |
Why?
| | Multivariate Analysis | 1 | 2017 | 390 | 0.040 |
Why?
| | Demography | 1 | 2016 | 83 | 0.040 |
Why?
| | Reference Standards | 1 | 2015 | 38 | 0.040 |
Why?
| | Health Status Disparities | 1 | 2016 | 70 | 0.040 |
Why?
| | Alcohol Drinking | 1 | 2016 | 86 | 0.040 |
Why?
| | Feeding Behavior | 1 | 2016 | 122 | 0.040 |
Why?
| | Self Report | 1 | 2016 | 225 | 0.030 |
Why?
| | Health Behavior | 1 | 2016 | 177 | 0.030 |
Why?
| | Muscle, Skeletal | 1 | 2018 | 385 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2016 | 362 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2015 | 467 | 0.030 |
Why?
| | United States | 1 | 2021 | 2539 | 0.030 |
Why?
| | Rural Health | 1 | 2013 | 9 | 0.030 |
Why?
| | Atrial Fibrillation | 1 | 2016 | 197 | 0.030 |
Why?
| | Diet | 1 | 2014 | 202 | 0.030 |
Why?
| | Urban Health | 1 | 2013 | 29 | 0.030 |
Why?
| | Hyperlipidemias | 1 | 2012 | 29 | 0.030 |
Why?
| | Confidence Intervals | 1 | 2012 | 102 | 0.030 |
Why?
| | Public Health | 1 | 2012 | 66 | 0.030 |
Why?
| | Reference Values | 1 | 2012 | 260 | 0.030 |
Why?
| | Adolescent | 1 | 2018 | 2667 | 0.030 |
Why?
| | Models, Statistical | 1 | 2011 | 144 | 0.030 |
Why?
| | Survival Rate | 1 | 2012 | 465 | 0.030 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2011 | 227 | 0.030 |
Why?
| | Electrophysiology | 1 | 2008 | 140 | 0.020 |
Why?
| | Electric Stimulation | 1 | 2008 | 87 | 0.020 |
Why?
| | Hand | 1 | 2008 | 49 | 0.020 |
Why?
| | Animals | 1 | 2017 | 5312 | 0.020 |
Why?
| | Ultrasonography | 1 | 2008 | 210 | 0.020 |
Why?
|
|
Oveisgharan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|